Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer (NCT07346807) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer
China69 participantsStarted 2026-01-01
Plain-language summary
The goal of this clinical trial is to evaluate the feasibility and preliminary efficacy of lingual nerve disruption combined with neoadjuvant chemoimmunotherapy in patients with locally advanced tongue squamous cell carcinoma.
The study aims to learn whether surgical disruption of the lingual nerve can enhance the effectiveness of neoadjuvant chemoimmunotherapy before definitive surgery in adults with locally advanced (cT3/T4) tongue cancer. The main questions it aims to answer are:
Can lingual nerve disruption combined with neoadjuvant chemoimmunotherapy improve tumor response prior to surgery?
Is this combined treatment approach safe and feasible for patients with locally advanced tongue cancer?
This is a single-arm, phase II clinical trial.
Participants will:
Undergo tumor biopsy with simultaneous surgical disruption of the affected-side lingual nerve.
Receive neoadjuvant chemoimmunotherapy consisting of tislelizumab, cisplatin, and nab-paclitaxel for two treatment cycles.
Undergo definitive surgical resection of the primary tumor and neck dissection.
Attend scheduled follow-up visits for safety assessments, imaging evaluations, and collection of blood samples for immune monitoring.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18-75 years, male or female.
✓. Histologically or cytologically confirmed primary tongue squamous cell carcinoma (cT3 or cT4).
✓. Patients scheduled to receive 2 cycles of preoperative neoadjuvant chemoimmunotherapy with tirelizumab, cisplatin, and albumin-bound paclitaxel.
✓. Patients planned to undergo surgical resection of tongue cancer following neoadjuvant therapy.
✓. Voluntary participation with signed informed consent, good compliance, and willingness to follow study procedures.
Exclusion criteria
✕. Known distant metastases of the tumor.
✕. History of tongue squamous cell carcinoma or other malignant tumors of the tongue within the past 5 years.
✕. Active infection requiring systemic therapy; non-infectious pneumonia or interstitial lung disease requiring steroid therapy, or current pneumonia/interstitial lung disease; known hepatitis B infection (HBsAg positive) or active hepatitis C infection (detectable HCV RNA); known HIV infection.
What they're measuring
1
Major Pathologic Response (MPR) Rate
Timeframe: From baseline (day1, before biopsy and lingual nerve disruption) to surgery (3 weeks after completion of 2 cycles of neoadjuvant therapy, which starts 1 week after the biopsy. Each cycle of neoadjuvant therapy is 21 days/3 weeks)
✕. Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, NYHA class ≥II heart disease within 3 months prior to enrollment).
✕. Active serious clinical infections (\>Grade 2 NCI-CTCAE v5.0).
✕. Uncontrolled hypertension (treated systolic BP \>150 mmHg and/or diastolic BP \>90 mmHg) or clinically significant cardiovascular disease, including recent cerebrovascular accident or myocardial infarction (≤6 months), unstable angina, NYHA class ≥II congestive heart failure, or severe arrhythmia not controlled by medication that could affect study treatment.